Abstract
Aim:
We investigated outcomes in patients with advanced non-small-cell lung cancer (NSCLC) and peritoneal involvement.
Patients & methods:
NSCLC patients with peritoneal carcinomatosis (PC) were included. We evaluated mOS1 (overall survival [OS] from NSCLC diagnosis) and mOS2 (OS from diagnosis of PC).
Results:
In total, 60 NSCLC patients were diagnosed with PC, 12 (20%) patients had a diagnosis of NSCLC and synchronous PC with a median OS of 9 months. Smokers had a shorter mOS1 and mOS2 compared with never-smokers; EGFR-mutated patients on tyrosine kinase inhibitors had longer mOS1 and mOS2 than EGFR wild-type patients.
Conclusion:
Metachronous PC is correlated to a short survival, irrespective of treatment line. Never-smokers and EGFR-mutated patients had improved mOS1 and mOS2 when compared with smokers and EGFR wild-type population.
Keywords:
peritoneal carcinomatosis; prognostic factors; survival; NSCLC.
MeSH terms
-
Adult
-
Age Factors
-
Aged
-
Aged, 80 and over
-
Antineoplastic Combined Chemotherapy Protocols / pharmacology
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carcinoma, Non-Small-Cell Lung / drug therapy
-
Carcinoma, Non-Small-Cell Lung / genetics
-
Carcinoma, Non-Small-Cell Lung / mortality*
-
Carcinoma, Non-Small-Cell Lung / secondary
-
ErbB Receptors / antagonists & inhibitors
-
ErbB Receptors / genetics
-
Female
-
Humans
-
Lung Neoplasms / drug therapy
-
Lung Neoplasms / genetics
-
Lung Neoplasms / mortality*
-
Lung Neoplasms / pathology
-
Male
-
Middle Aged
-
Mutation
-
Non-Smokers / statistics & numerical data
-
Peritoneal Neoplasms / drug therapy
-
Peritoneal Neoplasms / genetics
-
Peritoneal Neoplasms / mortality*
-
Peritoneal Neoplasms / secondary
-
Progression-Free Survival
-
Protein Kinase Inhibitors / pharmacology
-
Protein Kinase Inhibitors / therapeutic use*
-
Retrospective Studies
-
Sex Factors
-
Smokers / statistics & numerical data
Substances
-
Protein Kinase Inhibitors
-
EGFR protein, human
-
ErbB Receptors